MGI(SH:688114) Cai Jing Wang·2026-02-24 04:06Core Viewpoint - The company BGI Genomics announced the sale of its wholly-owned subsidiary Complete Genomics, Inc. (CGI) to SwissRockets for approximately $50 million, which is expected to enhance the company's profitability and operational efficiency through the divestiture of CGI's losses [1] Group 1: Transaction Details - The transaction involves a share purchase agreement for 100% equity of CGI, with the final price to be determined based on the closing conditions [1] - An amendment to the licensing agreement was signed, allowing SwissRockets to use Standard MPS sequencing technology and general sequencing technology for a fee [1] Group 2: Financial Impact - The company anticipates receiving no less than $120 million in licensing fees, which includes a $20 million upfront payment and future milestone payments [1] - The divestiture is expected to significantly improve direct revenue and cash flow for the company [1] Group 3: Strategic Focus - Post-transaction, the company will continue to lead the CoolMPS sequencing technology business in the Asia-Pacific and Greater China regions while indirectly participating in the North American market through the licensing model [1] - The transaction aims to optimize global resource allocation for the company [1]